LMR Partners LLP Acquires New Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

LMR Partners LLP bought a new position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,244,400 shares of the biopharmaceutical company's stock, valued at approximately $11,648,000. LMR Partners LLP owned approximately 2.14% of Revance Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. Swiss National Bank increased its holdings in Revance Therapeutics by 18.2% during the 1st quarter. Swiss National Bank now owns 194,650 shares of the biopharmaceutical company's stock worth $958,000 after purchasing an additional 30,000 shares during the period. Blair William & Co. IL increased its stake in Revance Therapeutics by 3.6% during the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company's stock worth $1,620,000 after buying an additional 11,318 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Revance Therapeutics by 6.5% in the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company's stock valued at $26,560,000 after acquiring an additional 328,781 shares during the last quarter. Natixis acquired a new position in Revance Therapeutics in the first quarter valued at approximately $391,000. Finally, CM Management LLC lifted its stake in Revance Therapeutics by 233.3% during the first quarter. CM Management LLC now owns 250,000 shares of the biopharmaceutical company's stock worth $1,230,000 after purchasing an additional 175,000 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Revance Therapeutics Trading Down 4.1 %

NASDAQ RVNC traded down $0.17 during trading on Monday, reaching $4.00. 1,135,519 shares of the company's stock were exchanged, compared to its average volume of 2,763,907. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $9.74. The firm has a market capitalization of $419.61 million, a PE ratio of -2.16 and a beta of 0.95. The company's fifty day simple moving average is $5.41 and its 200-day simple moving average is $4.45.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. Equities analysts forecast that Revance Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Piper Sandler lowered Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, August 12th. HC Wainwright reiterated a "neutral" rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. StockNews.com assumed coverage on shares of Revance Therapeutics in a research report on Monday. They issued a "hold" rating for the company. Finally, Guggenheim reiterated a "neutral" rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat, Revance Therapeutics has an average rating of "Hold" and an average price target of $9.66.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.